Skip to main content
Erschienen in: Inflammopharmacology 1/2022

24.01.2022 | Original Article

The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules

verfasst von: Kemal Ozan Lule, Ersin Akarsu, Zeynel Abidin Sayiner, Nezihe Otay Lule, Sibel Oguzkan Balci, Can Demirel, Zehra Bozdag, Murat Korkmaz, Ibrahim Yilmaz

Erschienen in: Inflammopharmacology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Obesity-induced inflammation mechanism is seen as a mechanism that may be the cause of insulin resistance and non-alcoholic fatty liver disease (NAFLD). Pathological destruction of insulin signaling molecules such as insulin receptor substrate proteins (IRS), especially due to the increase of cytokine signal suppressors (SOCS), has been demonstrated in experimental diabetes. The aim of this study was to determine the effects of metformin, pioglitazone, exenatide and exercise treatments used in type 2 diabetes on fatty liver and the role of Irs-1 and Socs3 molecules in this process in obese diabetic rats.

Methods

The study was conducted on 48 Wistar albino adult male rats weighing 180–220 g and randomly divided into 6 groups. The obese rat model with fatty liver was formed with a 60% fat diet for 4 weeks. Afterwards, drug treatment with metformin (Ob + D + M), pioglitazone (Ob + D + P), exenatide (Ob + D + ExA)) or exercise (Ob + D + ExE) was applied for 4 weeks to these obese groups, in which diabetes was induced by streptozocin (STZ). At the end of the experimental protocol, liver tissue samples were taken from all rat groups and histopathological and genetic analyses were performed.

Results

The mean steatosis degrees of the Ob + D + ExA and Ob + D + ExE groups were statistically significantly decreased compared to the obese diabetic group (p < 0.001). The group with the lowest mean steatosis grade was the Ob + D + ExE. Decrease in SOCS-3 expression was significant in Ob + D + M and Ob + D + P groups than other groups (p < 0.05). Mean staining intensities of Ob + D + Ex group, Ob + D + ExE group and Ob + D + P group according to IRS-1 expression statistically significantly increased compared to obese diabetic group (p < 0.05). Average staining intensity of Ob + D + ExE group according to IRS-1 expression was significant than other groups.

Conclusion

Exercise and exenatide treatments seemed to be the prominent treatment methods by showing a statistically significant effect in decreasing the degree of steatosis, decreasing the Socs3 expression level and increasing the Irs-1 expression level.
Literatur
Zurück zum Zitat Alhaider AA, Korashy HM, Sayed-Ahmed MM, Mobark M, Kfoury H, Mansour MA (2011) Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression. Chem Biol Interact 192(3):233–242CrossRef Alhaider AA, Korashy HM, Sayed-Ahmed MM, Mobark M, Kfoury H, Mansour MA (2011) Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression. Chem Biol Interact 192(3):233–242CrossRef
Zurück zum Zitat Bassi D, BuenoPde G, Nonaka KO, Selistre-Araujo HS, Leal AM (2015) Exercise alters myostatin protein expression in sedentary and exercised streptozotocin-diabetic rats. Arch Endocrinol Metab 59(2):148–153CrossRef Bassi D, BuenoPde G, Nonaka KO, Selistre-Araujo HS, Leal AM (2015) Exercise alters myostatin protein expression in sedentary and exercised streptozotocin-diabetic rats. Arch Endocrinol Metab 59(2):148–153CrossRef
Zurück zum Zitat Boettcher E, Csako G, Pucino F, Wesley R, Loomba R (2012) Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 35(1):66–75CrossRef Boettcher E, Csako G, Pucino F, Wesley R, Loomba R (2012) Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 35(1):66–75CrossRef
Zurück zum Zitat Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, Dhindsa S et al (2012) Exenatide exerts a potent anti inflammatory effect. J Clin Endocrinol Metab 97(1):198–207CrossRef Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, Dhindsa S et al (2012) Exenatide exerts a potent anti inflammatory effect. J Clin Endocrinol Metab 97(1):198–207CrossRef
Zurück zum Zitat Day C, Saksena S (2002) Non-alcoholic steatohepatitis: Definitions and pathogenesis. J Gastroenterol Hepatol 17:S377–S384CrossRef Day C, Saksena S (2002) Non-alcoholic steatohepatitis: Definitions and pathogenesis. J Gastroenterol Hepatol 17:S377–S384CrossRef
Zurück zum Zitat Diehl AM, Day C (2017) Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 377:2063–2072CrossRef Diehl AM, Day C (2017) Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 377:2063–2072CrossRef
Zurück zum Zitat Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic and clinical implications. Hepatology 51(2):679–689CrossRef Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic and clinical implications. Hepatology 51(2):679–689CrossRef
Zurück zum Zitat Feng X, Tang H, Leng J, Jiang Q (2014) Suppressors of cytokine signaling (SOCS) and type 2 diabetes. Mol Biol Rep 41(4):2265–2274CrossRef Feng X, Tang H, Leng J, Jiang Q (2014) Suppressors of cytokine signaling (SOCS) and type 2 diabetes. Mol Biol Rep 41(4):2265–2274CrossRef
Zurück zum Zitat Gunton JE, Delhanty PJ, Takahashi S, Baxter RC (2003) Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab 88(3):1323–1332CrossRef Gunton JE, Delhanty PJ, Takahashi S, Baxter RC (2003) Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab 88(3):1323–1332CrossRef
Zurück zum Zitat Haukeland JW, Konopski Z, Eggesbø HB, Volkmann HL, Raschpichler G, Bjøro K (2009) Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 44(7):853–860CrossRef Haukeland JW, Konopski Z, Eggesbø HB, Volkmann HL, Raschpichler G, Bjøro K (2009) Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 44(7):853–860CrossRef
Zurück zum Zitat Khan RS, Bril F, Cusi K, Newsome PN (2019) Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology 70(2):711–724PubMed Khan RS, Bril F, Cusi K, Newsome PN (2019) Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology 70(2):711–724PubMed
Zurück zum Zitat Kim YD, Kim YH, Cho YM, Kim DK, Ahn SW, Lee JM et al (2012) Met for min ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models. Diabetologia 55(5):1482–1494CrossRef Kim YD, Kim YH, Cho YM, Kim DK, Ahn SW, Lee JM et al (2012) Met for min ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models. Diabetologia 55(5):1482–1494CrossRef
Zurück zum Zitat Lau JKC, Zhang X, Yu J (2017) Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol 241:36–44CrossRef Lau JKC, Zhang X, Yu J (2017) Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol 241:36–44CrossRef
Zurück zum Zitat Lavin DP, White MF, Brazil DP (2016) IRS proteins and diabetic complications. Diabetologia 59(11):2280–2291CrossRef Lavin DP, White MF, Brazil DP (2016) IRS proteins and diabetic complications. Diabetologia 59(11):2280–2291CrossRef
Zurück zum Zitat Linossi EM, Calleja DJ, Nicholson SE (2018) Understanding SOCS protein specificity. Growth Factors 36(3–4):104–117CrossRef Linossi EM, Calleja DJ, Nicholson SE (2018) Understanding SOCS protein specificity. Growth Factors 36(3–4):104–117CrossRef
Zurück zum Zitat Liu X, Qian X, Tu R, Mao Z, Huo W, Zhang H et al (2020) SOCS3 methylation mediated the effect of sedentary time on type 2 diabetes mellitus: The Henan Rural Cohort study. Nutr Metab Cardiovasc Dis 30(4):634–643CrossRef Liu X, Qian X, Tu R, Mao Z, Huo W, Zhang H et al (2020) SOCS3 methylation mediated the effect of sedentary time on type 2 diabetes mellitus: The Henan Rural Cohort study. Nutr Metab Cardiovasc Dis 30(4):634–643CrossRef
Zurück zum Zitat Liu L, Yan H, Xia M, Zhao L, Lv M, Zhao N et al (2020) Efficacy of exenatideandinsulinglargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev 36(5):e3292CrossRef Liu L, Yan H, Xia M, Zhao L, Lv M, Zhao N et al (2020) Efficacy of exenatideandinsulinglargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev 36(5):e3292CrossRef
Zurück zum Zitat Manowsky J, Camargo RG, Kipp AP, Püschel GP (2016) Insulin-induced cytokine production in macrophages causes insulin resistance in hepatocytes. Am J Physiol Endocrinol Metab 310(11):E938-946CrossRef Manowsky J, Camargo RG, Kipp AP, Püschel GP (2016) Insulin-induced cytokine production in macrophages causes insulin resistance in hepatocytes. Am J Physiol Endocrinol Metab 310(11):E938-946CrossRef
Zurück zum Zitat Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116(6):1413–1419CrossRef Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116(6):1413–1419CrossRef
Zurück zum Zitat Orci LA, Gariani K, Oldani G, Delaune V, Morel P, Toso C (2016) Exercise-based Interventions for Nonalcoholic Fatty Liver Disease: A Meta-analysis and Meta-regression. Clin Gastroenterol Hepatol 14(10):1398–1411CrossRef Orci LA, Gariani K, Oldani G, Delaune V, Morel P, Toso C (2016) Exercise-based Interventions for Nonalcoholic Fatty Liver Disease: A Meta-analysis and Meta-regression. Clin Gastroenterol Hepatol 14(10):1398–1411CrossRef
Zurück zum Zitat Ortiz-Lopez C, Lomonaco R, Orsak B (2012) Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 35:873–878CrossRef Ortiz-Lopez C, Lomonaco R, Orsak B (2012) Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 35:873–878CrossRef
Zurück zum Zitat Rinella ME (2015) Nonalcoholic fatty liver disease. JAMA 313:2263–2273CrossRef Rinella ME (2015) Nonalcoholic fatty liver disease. JAMA 313:2263–2273CrossRef
Zurück zum Zitat Sawangjit R, Chongmelaxme B, Phisalprapa P, Saokaew S, Thakkinstian A, Kowdley KV et al (2016) Comparativeefficacy of interventions on nonalcoholicfattyliverdisease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. Medicine (baltimore) 95(32):e4529CrossRef Sawangjit R, Chongmelaxme B, Phisalprapa P, Saokaew S, Thakkinstian A, Kowdley KV et al (2016) Comparativeefficacy of interventions on nonalcoholicfattyliverdisease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. Medicine (baltimore) 95(32):e4529CrossRef
Zurück zum Zitat Shao N, Kuang HY, Hao M, Gao XY, Lin WJ, Zou W (2014) Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes/metabol Res Rev 30(6):521–529CrossRef Shao N, Kuang HY, Hao M, Gao XY, Lin WJ, Zou W (2014) Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes/metabol Res Rev 30(6):521–529CrossRef
Zurück zum Zitat Sharma M, Mohapatra J, Malik U, Nagar J, Chatterjee A, Ramachandran B et al (2017) Effect of pioglitazone on metabolic features in endotoxemia model in obese diabetic db/db mice. J Diabetes 9(6):613–621CrossRef Sharma M, Mohapatra J, Malik U, Nagar J, Chatterjee A, Ramachandran B et al (2017) Effect of pioglitazone on metabolic features in endotoxemia model in obese diabetic db/db mice. J Diabetes 9(6):613–621CrossRef
Zurück zum Zitat Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D et al (2011) Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technol Assess 15(38):1–110CrossRef Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D et al (2011) Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technol Assess 15(38):1–110CrossRef
Zurück zum Zitat Wang ST, Zheng J, Peng HW, Cai XL, Pan XT, Li HQ et al (2020) Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. BMC Gastroenterol 20(1):66CrossRef Wang ST, Zheng J, Peng HW, Cai XL, Pan XT, Li HQ et al (2020) Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. BMC Gastroenterol 20(1):66CrossRef
Zurück zum Zitat Younossi Z, Tacke F, Arrese M, Sharma BC, Mostafa I, Bugianesi E et al (2019) Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology 69(6):2672–2682CrossRef Younossi Z, Tacke F, Arrese M, Sharma BC, Mostafa I, Bugianesi E et al (2019) Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology 69(6):2672–2682CrossRef
Metadaten
Titel
The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules
verfasst von
Kemal Ozan Lule
Ersin Akarsu
Zeynel Abidin Sayiner
Nezihe Otay Lule
Sibel Oguzkan Balci
Can Demirel
Zehra Bozdag
Murat Korkmaz
Ibrahim Yilmaz
Publikationsdatum
24.01.2022
Verlag
Springer International Publishing
Erschienen in
Inflammopharmacology / Ausgabe 1/2022
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-021-00916-6

Weitere Artikel der Ausgabe 1/2022

Inflammopharmacology 1/2022 Zur Ausgabe